Indications and uses
XCOPRI is indicated for the treatment of partial-onset seizures in adult patients.
XCOPRI is indicated for the treatment of partial-onset seizures in adult patients.
XCOPRI is indicated for the treatment of partial-onset seizures in adult patients.
Every source-derived product name is available through these pages.
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| CENOBAMATE | P85X70RZWS | ACTIB |
| CENOBAMATE | P85X70RZWS | ACTIB |
| CENOBAMATE | P85X70RZWS | ACTIB |
| CENOBAMATE | P85X70RZWS | ACTIB |
| CENOBAMATE | P85X70RZWS | ACTIB |
| CENOBAMATE | P85X70RZWS | ACTIB |
| CENOBAMATE | P85X70RZWS | ACTIB |
| CENOBAMATE | P85X70RZWS | ACTIB |
| CENOBAMATE | P85X70RZWS | ACTIB |
| CENOBAMATE | P85X70RZWS | ACTIB |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 180c2238-f5f5-e191-e063-6394a90a9bca | 0f2c0e91-f75a-5b29-e063-6294a90abf1a | 2024-05-09 | 0f2c0e91-f75a-5b29-e063-6294a90abf1a |
Adverse event summaries are temporarily unavailable. Other product information remains available.